All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

NCT05345002 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Glioma
IDH Mutation
Astrocytoma
Oligodendroglioma

Interventions

DRUG: Retifanlimab
DRUG: All-trans retinoic acid

Sponsor

Stephen Bagley, MD, MSCE

Collaborators

[object Object]
[object Object]